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Use of alternative donors/sources of hematopoietic stem cells (HSC), such as cord blood
(CB) or HLA-haploidentical (Haplo)-related donors, is associated with a significant delay
in immune reconstitution after transplantation. Long-term T-cell immune reconstitution
largely relies on the generation of new T cells in the recipient thymus, which can
be evaluated through signal joint (sj) and beta T-cell-Receptor Excision Circles (TREC)
quantification. We studied two groups of 33 and 24 children receiving, respectively, HSC
Transplantation (HSCT) from an HLA-haploidentical family donor or an unrelated CB donor,
for both malignant (46) and non-malignant disorders (11). Relative and absolute sj and
beta-TREC values indicated comparable thymic function reconstitution at 3 and 6 months
after the allograft in both groups. Compared to children with non-malignant disorders,
those with hematological malignancies had significantly lower pre-transplantation TREC
counts. Patients who relapsed after HSCT had a significantly less efficient thymic function
both before and 6 months after HSCT with especially low beta-TREC values, this finding
suggesting an impact of early intra-thymic T-cell differentiation on the occurrence of
leukemia relapse.
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INTRODUCTION
Whenever an HLA-identical related donor is not available,
alternative sources of donors/stem cells are to be used for
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
(Beatty et al., 1995). Both unrelated Cord Blood (CB) and
HLA-haploidentical (Haplo) family donors provide an effective
treatment for many malignant and non-malignant diseases in
children (Rocha and Locatelli, 2008). For the latter, the HLA
disparity in the donor/recipient pair may lead to a beneficial
and selective graft-versus-leukemia (GVL) effect, associated with
natural killer (NK)-cell mediated alloreactivity (Ruggeri et al.,
2002). Despite improvement in the graft procedure such as use
of T-cell depletion (TCD) and infusion of high doses of CD34+
cells, which allows engraftment and reduces graft-versus-host
disease (GvHD) in Haplo-HSCT recipients (Aversa et al., 1994;
Handgretinger et al., 2001), a significant delay in immune recon-
stitution still remains a relevant problem, leading to a high
incidence of both opportunistic infection and, in the absence of
NK alloreactivity, to relapse (Ball et al., 2005; Wils et al., 2011). In
this respect, association between poor clinical outcome and low
lymphocyte counts early after CB- or Haplo-HSCT (Ciurea et al.,
2011) or at month 6 in case of T-cell depleted HSCT (Novitzky
et al., 2002) has been described. Moreover, we showed recently,
in 33 Haplo-HSCT patients an association between low thymic
function and an increased risk of leukemia relapse (Clave et al.,
2012).
Recently, tools have been developed to monitor thymic
function. Signal-joint T-cell-Receptor (TCR) Excision Circles
(sjTREC) are small episomal DNA that results from the deletion
of the TCR δ region during TCR α locus rearrangement. They
are not replicated during lymphocyte cell division and reflect, in
the periphery, the number of new lymphocytes generated in the
thymus (Douek et al., 1998; Dion et al., 2007). BetaTREC are pro-
duced during TCR Dβ–Jβ recombination, occurring before TCR
α-chain recombination in αβ T-cell differentiation. BetaTREC
counts may therefore reflect the early stages of intrathymic dif-
ferentiation and sj/beta TREC ratios the T-cell proliferation rate
between β- and α-chain recombination events. Quantification of
sj and beta-TREC molecules in peripheral blood cells has pro-
vided useful information in studies addressing the issues of aging,
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HIV infection, and HSCT (Dion et al., 2004, 2007), but have
not yet been used in the context of studies on leukemia relapse
after HSCT.
In view of these considerations, we decided to investigate
thymic function recovery in patients given unrelated donor CB
transplantation (UCBT) and to compare the results obtained in
this cohort of patients with those of children given Haplo-HSCT.
In detail, we retrospectively evaluated thymic function recovery
through sj and beta TREC quantification in 57 pediatric patients,
33 receiving Haplo-HSCT previously reported and 24 given
UCBT. Thymic function recovery was found to be similar in
both groups. Moreover, correlation of TREC values with clinical
parameters revealed a link between recovery of thymic function
and specific disease. Indeed, we found that pre-transplantation sj
and beta TREC were lower for patients with malignant disease.
Moreover, there was a strong correlation between low thymic
function persisting at 6 month after HSCT and a higher incidence
of relapse in the Haplo-HSCT group.
PATIENTS
Two groups of pediatric patients, 24 receiving UCBT and 33 given
Haplo-HSCT (Table 1) for either malignant or non-malignant
diseases were studied, the last group being the same reported in
our previously published study (Clave et al., 2012). In order to be
included, patients had to be alive 6 months after transplantation
(so, 3 patients that relapsed before 6 months were also included).
All patients had been transplanted between October 2004 and
February 2007 after having received a fully-myeloablative con-
ditioning regimen. Details on patient and donor characteristics,
as well as on transplantation outcome, are reported in Table 1.
Table 1 | Patient-, donor-characteristics, and transplant outcomes.
Haplo-HSCT UCBT p
N = 33 N = 24
RECIPIENT
Male, N (%) 23 (70%) 14 (58%) 0.411
Median age, years (range) 7.7 (3–17) 4.7 (1–16) <0.001
Hematological malignancies 27 (82%) 19 (79%) 0.999
Acute lymphoblastic leukemia 20 11
Acute myeloid leukemia 3 6
Myelodysplastic syndromes 3 0
Juvenile myelomonocytic leukemia 1 2
Other diagnosis
Hemophagocytic lymphohistiocytosis 0 5
Fanconi anemia 3 0
Congenital amegakaryocytic thrombocytopenia 2 0
Blackfan-Diamond anemia 1 0
TRANSPLANTATION
Source of cells PB/CB 33/0 0/24 <0.001
Conditioning regimena: TBI/chemo-based 24/9 9/15 0.014
GvHD prophylaxisb: TCD/CsA + steroids 33/0 0/24 <0.001
Infused CD34+ cells: Median (range) × 106/Kg 22 (8.7–41)
Infused nucleated cells: Median (range) × 107/Kg 5.05 (1.4–12.5)
CLINICAL OUTCOMES
Acute GvHD
Grade (I/II/III/IV) 6/4/1/0 4/8/1/0
Grade II–IV 5 (15%) 9 (37%) 0.067
Chronic GvHD 6 (18%) 2 (8%) 0.446
Relapse 8 (24%) 3 (12%) 0.326
Serious infectionsc 20 (61%) 13 (54%) 0.786
Haplo-HSCT indicates HLA-Haploidentical Hematopoietic Stem Cell Transplantation; UCBT, Unrelated Cord Blood Transplantation; CsA, cyclosporin A; GvHD,
graft-versus-host disease; PB, peripheral blood; TBI, total body irradiation.
aTBI-based conditioning regimen was employed in 33 children and consisted of: fractionated TBI (12 Gy over 6 fractions in 3 days), Thiotepa (10 mg/Kg in 2 doses)
and fludarabine (160 mg/m2 over 4 days). Chemotherapy-based conditioning regimen were as follows: 12 patients received Busulfan (16 mg/Kg in 16 doses over 4
days), Cyclophosphamide (120 mg/Kg in 2 days) and melphalan (140 mg/m2 in single dose); 7 children received Busulfan (16 mg/Kg in 16 doses over 4 days), Thiotepa
(10 mg/Kg in 2 doses) and fludarabine (160 mg/m2 over 4 days); and 5 children were given Treosulfan (14 gr/m2 for 3 consecutive days), Thiotepa (10 mg/Kg in 2
doses) and fludarabine (160 mg/m2 over 4 days).
bPatients receiving Haplo-HSCT were transplanted with CD34+ selected cells and were not given any immune-suppressive drug after transplantation. Patients
transplanted with cord blood cells received a combination of Cyclosporine-A (3 mg/Kg/day) and steroids [methylprednisolone (2 mg/Kg/day)] as GvHD prophylaxis.
cReactivation of viral infections (i.e., cytomegalovirus and Epstein-Barr virus) and proven/probable invasive aspergillosis.
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No patient given Haplo-HSCT received post-transplantation
pharmacologic immune suppression, while those transplanted
with CB cells received a combination of CsA and steroids
(see also Table 1 for details). For the purpose of the study,
patients with acute leukemia transplanted in 1st complete remis-
sion (CR) or in 2nd CR after a relapse occurring more than
6 months after treatment discontinuation, as well as patients
affected by refractory cytopenia, were assigned to the early dis-
ease group. All other patients were included in the advanced
disease group. Acute and chronic GvHD (cGvHD) were diag-
nosed and graded according to the Seattle criteria (Glucksberg
et al., 1974; Storb et al., 1983). Patients surviving more than 14
and 100 days post-transplantation were evaluated for acute and
cGvHD, respectively. The study was approved by the Ethical com-
mittee of Policlinico San Matteo, Pavia, Italy (approval number
446/DG).
METHODS
DESIGN OF THE STUDY
DNA samples of patients enrolled in the study were collected
before transplantation and at 3 and 6 months after the allo-
graft. At the same time-points, we evaluated absolute number and
percentage of the different T lymphocyte subsets.
sjTREC AND beta-TREC QUANTIFICATION
Genomic DNA was extracted from Peripheral Blood
Mononuclear Cells (PBMC) using the QIAamp DNA Blood
Minikit (Qiagen, Hilden, Germany). Quantification of sjTREC
and beta-TREC was performed by real-time quantitative PCR
(qPCR) (ABIPRISM7500, Applied Biosystems, Foster City,
CA), as previously described (Clave et al., 2009). Briefly, a first
PCR reaction was carried out in multiplex with 3 different
outer primer mixes, 1–5μg of genomic DNA, 200μM each
dNTP, 2.5mM MgCl2, 1× buffer and 1.25 unit of Platinum®
Taq polymerase (Invitrogen, Cergy-Pontoise, France) in 50μL
(10min at 95◦C, then 19 cycles of 95◦C, 30 s; 60◦C, 30 s
and 72◦C, 2min). Final quantification was made on ABI
PRISM 7700, in duplicate with a second multiplex reaction
that contains 5μL of a 1/100 or 1/1000 dilution of the first
PCR product, inner primers, and probe for sjTREC or one
of the Dβ–Jβ segments, inner primers and probe for albumin
(alb) gene, 1.25mM each dNTP, 3mM MgCl2, 1× buffer
and 1.25 unit of Platinum® Taq polymerase in 25μL (5min
at 95◦C then 40 cycles of 95◦C, 15 s and 60◦C, 1min). The
sum of the 10 Dβ–Jβ segments was finally multiplied by 1.3
to extrapolate for all the 13 existing Dβ–Jβ segments. All
primers and probes have been obtained from Eurogentec
(Seraing, Belgium) except the alb vic-labeled probe from Applied
Biosystems.
TREC data were validated only if at least 50,000 genome
equivalents were detected by alb qPCR; therefore, some
time-points were missing for 5 patients but other negative
TREC values were not due to absence of genomic DNA.
Data were first expressed per 150,000 PBMC and the total
number of TREC per μL of blood was calculated using
the absolute white blood cells count at time of sample
collection.
FLOW CYTOMETRY ANALYSIS
FITC, PE, PerCP, or APC monoclonal antibodies (MoAbs) spe-
cific for the following antigens were employed for the evaluation
of lymphocyte subsets: CD45, CD3, CD4, CD8 (BD Biosciences,
Mountain View, CA). Appropriate isotype-matched controls (BD
Bioscience) were included. Three-color or four-color cytome-
try, through direct immune fluorescence and FACSCalibur or
FACSCanto cytometer (BD Biosciences), was performed.
STATISTICAL ANALYSIS
Non-parametric Mann–Whitney or Kruskal–Wallis tests were
used to correlate the effect of different clinical parameters on
TREC counts. Since data did not have a normal distribution, a
logarithmic transformation was performed. Difference in cumu-
lative incidence of relapse was estimated using univariate Kaplan–
Meier analysis. P-values <0.05 were considered to be statistically
significant. All analyses were performed using SPSS Statistics 20
Software.
RESULTS
THYMIC FUNCTION RECOVERY IS SIMILAR AFTER HAPLO-HSCT AND
UCBT IN PEDIATRIC PATIENTS
The distribution of circulating CD3+, CD4+, or CD8+
T-lymphocyte subsets, 3 and 6 months after HSCT, was variable,
especially for patients given Haplo-HSCT (Table 2). At month
3, CD3+, CD4+, and CD8+ cell counts/μL blood were lower
in Haplo-HSCT than in UCBT patients (p = 0.003, 0.005, and
0.010, respectively). At month 6, only CD4+ cells remained sig-
nificantly lower (p = 0.022) in the former group. These results
confirm the detrimental role of TCD of the graft on early recon-
stitution of mature T cells and the role played by homeostatic
expansion of T cells transferred with the graft in the case of UCBT
(Roux et al., 1996).
Reconstitution of newly generated naïve T cells relies on
thymic differentiation of donor-derived lymphoid progenitors.
We, therefore, evaluated recovery of thymic function through the
quantification of sjTREC and beta-TREC on the samples collected
at the same points in which lymphocyte counts were investigated.
Before the allograft, the median number of sjTREC per 150,000
PBMC were 1375 (range 0–27,612) and 2035 (range 0–16,626)
for Haplo-HSCT andUCBT patients, respectively (p = not signif-
icant, NS). Three months after the allograft the median number
of sjTREC per 150,000 PBMC had dropped to 27 (0–1973) and 45
(0–1284) for Haplo-HSCT and UCBT patients, respectively. At 6
months, although there was a great inter-patient variability, the
median number of sjTREC numbers almost returned to pre-graft
levels with 281 (0–31,286) and 647 (0–16,395) sjTREC/150,000
PBMC, for Haplo-HSCT and UCBT patients (Figure 1A), respec-
tively. The recovery of betaTREC paralleled that of sjTREC
(Figure 1B) without any significant difference between the two
groups of patients. Accordingly, at each time points, the num-
ber of sjTREC highly correlated with the number of beta-TREC
(r = 0.66, p < 0.001, Pearson correlation).
Since proliferation of memory or effector T cells could affect
TREC number per PBMC by dilution, we also expressed sjTREC
and beta-TREC counts per microliter of patient blood using abso-
lute cell counts. Absolute numbers of sjTREC (Figure 1C) and
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Table 2 | Median number (range) of circulating T-lymphocyte subsets three (M3) and six (M6) months after HSCT (cells ×103/µl).
M3 M6
N CD3+ CD4+ CD8+ N CD3+ CD4+ CD8+
All patients
Haplo 33 264 (0–2666) 68 (0–1767) 80 (0–1666) 30 610 (140–2992) 242 (88–760) 270 (14–2596)
UCBT 23 540 (180–4661) 190 (72–885) 280 (18–4092) 21 852 (352–6440) 336 (105–1288) 456 (80–5152)
p 0.003 0.005 0.010 0.058 0.022 0.151
Malignant Haplo-HSCT
Relapse 8 279 (4–572) 29 (0–264) 84 (0–308) 7 867 (154–2460) 234 (98–369) 480 (14–2132)
CR 19 252 (0–2666) 138 (0–1767) 63 (0–1666) 17 560 (140–2992) 273 (88–546) 248 (14–2596)
p 0.894 0.300 0.831 0.193 0.975 0.075
Malignant UCBT
Relapse 3 1040 (266–4661) 234 (91–885) 819 (154–3540) 3 1250 (852–1288) 324 (250–529) 759 (516–1000)
CR 15 715 (180–4465) 153 (72–616) 476 (18–4092) 14 811 (352–6440) 322 (105–1288) 442 (80–5152)
p 0.441 0.594 0.441 0.314 0.801 0.313
M3 stands for Month 3; M6, Month 6, and CR, Complete remission.
beta-TREC (Figure 1D) followed the same kinetics as numbers of
TREC/150,000 PBMC, without difference between Haplo-HSCT
and UCBT patients, this ruling out an indirect, confounding
effect of T-cell proliferation. Only absolute sj and beta-TREC
numbers per μL will be used afterwards.
Since sjTREC value as a marker of thymic output is dependent
on age (Douek et al., 1998), we also compared the median age
of patients in the two groups. Haplo-HSCT patients were indeed
significantly older (p = 0.0008) than UCBT patients (median age
being 7.7 and 4.7 years, range 3–17 and 0.75–16 years, respec-
tively). Thus, from the observed TREC values, we can conclude
that, despite an older age, thymic reconstitution was equally
effective in patients given either Haplo-HSCT or UCBT.
Since GvHD has a major impact on immune reconstitution
after allogeneic HSCT, we studied its influence on both groups of
patients. There were less cases of acute GvHD (aGvHD) in Haplo-
HSCT patients (Table 1). We did not see any significant difference
for sjTREC/μL of blood between patients without or with grade
I aGvHD and patients with grade II and III aGvHD (Figure 1E),
in both groups of patients. Incidence of cGvHD was low in both
groups with 6 (18%) and 2 cases (8%) in the Haplo-HSCT and
UCBT cohorts, respectively. TREC values were lower at month 6,
in both groups, when cGvHDoccurred, but the difference was not
statistically significant (Figure 1F).
PATIENTS AFFECTED BY HEMATOLOGICAL MALIGNANCIES HAVE
LOWER PRE-TRANSPLANT THYMIC FUNCTION
Diagnosis may also have an impact on recovery of thymic func-
tion (Petridou et al., 2002; Clave et al., 2005). Indeed, TREC
values before transplantation were significantly lower in the 46
patients with hematological malignancies (median 10 sjTREC/μL
blood, range 0–674) than in the 11 with non-malignant disor-
ders (median, 235 sjTREC/μL blood, range 97–1340, p = 0.0002)
(Figure 2). This finding was not influenced by the type of allograft
that the patients received (data not shown). There was no signifi-
cant difference in age between the two groups of patients, affected
or not by hematological malignancy (median 6.6 vs. 5.0 years,
range 1–9 vs. 1–17, p = 0.18) that could explain a lower thymic
function in patients with malignancy. Before transplantation,
patients with early disease had higher sj and beta-TREC than
those with more advanced disease (Figure 2). Moreover, median
numbers of betaTREC/μL of blood were also significantly lower
in patients treated for malignancies (median 1.7 vs. 39, p =
0.004) (Figure 2), suggesting an effect of the disease itself or
of previous treatment on the T-cell progenitor compartment or
before β-chain recombination.
A LOW THYMIC FUNCTION IS ASSOCIATED WITH A HIGHER
RELAPSE RISK
We have previously shown in the group of Haplo-HSCT patients
that a low thymic function before transplantation or after
6 months, was associated with an increased risk of relapse (Clave
et al., 2012). Here, thymic reconstitution appears similar after
both UCBT and Haplo-HSCT. Thus, we decided to merge the
19UCBT to the 27 Haplo-HSCT cases affected by malignan-
cies. Among the 46 patients treated for malignancies, 11 relapsed:
8 after Haplo-HSCT and 3 after UCBT (see Table 1). The median
time between transplantation and relapse was 10 months (range
1.6–18 months).
When considering both patients given UCBT and those receiv-
ing Haplo-HSCT, the median number of sjTREC/μL blood was
low at 3 months and returned to the initial level at month 6.
With amedian follow-up of 43months, patients who relapsed had
lower values than the relapse-free patients both before transplan-
tation (p < 0.05) and during follow-up (p = 0.014 and 0.006,
at 3 and 6 months, respectively) (Figure 3A). Values of beta-
TREC before transplantation and, even more significantly, after
6 months (Figure 3B) were also lower in patients who subse-
quently relapsed (p = 0.037 and 0.009, respectively).
We also carefully evaluated the occurrence of relapse in
patients with a poor thymic function. We calculated the cumu-
lative incidence of relapse in patients with a detectable thymic
function compared to those without any thymic function (based
on the detection sensitivity of the sj and beta TREC assays less
than 0.1 and 0.01/150,000 PBMC, respectively). Because values
at month 3 were too low to define this cut-off reliably, we stud-
ied only the values before transplantation and those at month 6
post transplantation. Absence of detectable sjTREC at each time
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FIGURE 1 | Thymic reconstitution is not dependent on the stem cell
source employed or GvHD occurrence. Mean (±SE) number of log10 TREC
was measured by quantitative PCR, before, and 3 and 6 months after
transplantation in patients that received either a haploidentical hematopoietic
Stem Cell Transplantation (Haplo, N = 33) or a Cord Blood Unrelated Donor
Graft (CB, N = 24). Signal Joint (sj) TREC were quantified in (A,C,E, and F)
and betaTREC in (B and D). Results were expressed by 150,000 Peripheral
Blood Mononuclear Cells in (A and B) and by μL of blood in (C,D,E, and F).
Patients were subsequently subdivided according to GvHD occurrence
(E and F).
point correlated with an increased incidence of relapse, although
this correlation was not statistically significant, due to the lim-
ited number of events (data not shown). More notably, lack of
detectable betaTREC before and at month 6 after the allograft
was strongly associated to a higher incidence of relapse (p =
0.03 and 0.02, respectively) (Figures 3C,D). Use of median sj or
beta-TREC value to split patient groups as low or high TREC gave
similar results (data not shown). We also analyzed, in patients
treated for malignancies, other parameters that have been shown
to influence relapse rate, but neither age (p = 0.28), high-risk
disease (p = 0.73), conditioning regimen (p = 0.24) nor num-
ber of CD34+ cells infused (for Haplo-HSCT patients, p = 0.72)
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FIGURE 2 | Thymic function before transplantation is lower in patients
affected by a hematological malignancy. Log10 sjTREC/blood μL (A) and
Log10 betaTREC/blood μL (B) are shown before HSCT for patients diagnosed
with either a malignant or a non-malignant hematological disease. Patients
with malignancy were subsequently subdivided according to their disease
status. Horizontal bars represent the median.
had a significant impact on relapse in univariate analysis in this
relatively small cohort of patients.
DISCUSSION
Alternative sources of stem cells/donors are increasingly used
in the treatment of children with both malignant and non-
malignant diseases in need of an allograft (Copelan, 2006).
However, their use remains associated with delayed immune
reconstitution and a high rate of infectious complications
(Aversa et al., 1998). Using sj and beta-TREC quantification,
we found that thymic function had the same pattern of recon-
stitution in patients that had been transplanted from either an
HLA haploidentical family donor or an unrelated CB donor
despite the difference in stem cell source and transplant pro-
cedure. It is known that TCD of the graft (in vivo or ex vivo)
has a huge impact on early reconstitution of the lymphocyte
compartment, since patients cannot benefit from the home-
ostatic expansion of lymphocytes transferred with the graft
(Roux et al., 1996). Accordingly, we found that reconstitution
of T-cell subset numbers (i.e., CD4+ and CD8+ T cell sub-
populations) was faster in UCBT patients than in those given
Haplo-HSCT. However, median values of beta and sjTREC were
similar in both groups, this indicating that, despite TCD of the
graft, a larger use of total body irradiation (Table 1) and an
older age for Haplo-HSCT recipients, recovery of thymic func-
tion was equally effective in patients given either Haplo-HSCT
or UCBT. These results also illustrate that the TREC assay
provides additional and more detailed information on T-cell
reconstitution, in particular on that of newly re-generated
T lymphocytes which mainly accounts for the medium and long-
term patient’s immune competence, than crude T cell subsets
counts.
We found a very limited impact of GvHD (Hazenberg et al.,
2002; Storek et al., 2002; Clave et al., 2009), and especially of
aGvHD, on recovery of thymic function in both groups. This
could be explained by both the limited incidence of this com-
plication in the 2 groups and by the young age of our patients.
Indeed, in a previous study we reported that young age at time
of the allograft correlates with a better thymic function recovery
(Clave et al., 2009).
In accordance with what we and others have previously shown
(Petridou et al., 2002; Chen et al., 2005; Clave et al., 2005),
patients with malignant diseases had lower TREC values already
before the allograft than those with non-malignant disorders.
However, in those previously published studies, the groups were
not matched for age (Petridou et al., 2002; Clave et al., 2005) and
only the relative number of TREC was assessed (Petridou et al.,
2002; Chen et al., 2005), leaving the possibility of TREC dilution
due to peripheral proliferation. Here, the median age in groups of
patients affected by either a malignant or a non-malignant dis-
ease was similar and the number of TREC was given for unit
of blood volume. Moreover, we specifically assessed beta-TREC,
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FIGURE 3 | A low thymic function is associated with a higher relapse
risk. Mean (±SE) number of log10 sjTREC/ Blood μL (A) and betaTREC/
Blood μL (B), before, 3 and 6 months after transplantation in patients
with hematological malignancies that received either a T-cell depleted
haploidentical Hematopoietic Stem Cell Transplantation or an Unrelated
Donor Cord Blood Transplantation (Mal.) or the former type of allograft
only (Haplo). Patients who experienced relapse were represented with
gray dotted lines, while patients maintaining complete remission with
black plain lines. ∗p < 0.05, ∗∗p < 0.01. Cumulative incidence of relapse in
patients affected by malignant disorders who did or did not have
detectable betaTREC before (C), and at month 6 after graft (D)
(p in Log Rank test).
a marker of intrathymic proliferation of T-cells undergoing dif-
ferentiation. Beta-TREC values were also reduced in patients with
malignancies, suggesting a mechanistic impact of the disease itself
or its treatment on T-cell generation before beta chain TCR
recombination, i.e., at the progenitor level and/or after homing
to the thymus. In this respect, previous studies indicating the lack
of association between TREC and chemotherapy (Petridou et al.,
2002; Chen et al., 2005), could argue for a direct impact of hema-
tological malignancy on thymic function rather than for a role of
previous treatment.
In conclusion, we have previously shown an association
between low levels of sj and beta-TREC and disease recurrence in
the group of 27 haplo-HSCT patients with malignancies (Clave
et al., 2012). Given the similarity in thymic function recovery of
these patients with those treated with UCBT, by adding to the
analysis the results obtained for these patients, we could increase
to 46 the total number of patient treated for malignancies. With
this addition, patients who relapsed still had a lower count of sj
and beta TREC (Figures 3A,B) and patients with a low value of
beta-TREC, both before and atmonth 6 after transplantation, had
a significantly higher incidence of relapse (Figures 3C,D). Since
the cohort size did not allow us to perform a multivariate anal-
ysis, we cannot exclude that the effect on relapse could be due
to other disease variable. However, none of the different clinical
parameters we tested such as disease risk or patient age, had a
significant effect on relapse in univariate analysis. Therefore, the
significant correlation of beta-TREC with relapse 6 months after
transplantation suggest that a post-graft thymic differentiation of
naïve T cells with anti-leukemia potential could play a crucial role
in preventing relapse and mediating GVL.
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